CIHR Collaborative Health Research Projects (CHRP)

Size: px

Start display at page:

Download "CIHR Collaborative Health Research Projects (CHRP)"

Tabitha Dawson
5 years ago
Views:

1 CIHR Collaborative Health Research Projects (CHRP) Information Session April 12, 2013 Presented by: Jody Swift CIHR Contact: Krissy Davidge, Senior Advisor Knowledge Translation 1

2 Slide courtesy of Krissy Davidge, CIHR 2

A Collaborative Funding Initiative Minister of Health Minister of Industry CIHR's mandate is to "excel, according to internationally accepted standards of scientific excellence, in the creation of

3 A Collaborative Funding Initiative Minister of Health Minister of Industry CIHR's mandate is to "excel, according to internationally accepted standards of scientific excellence, in the creation of new knowledge and its translation into improved health for Canadians, more effective health services and products and a strengthened Canadian health-care system." NSERC aims to make Canada a country of discoverers and innovators for the benefit of all Canadians. The agency supports university students in their advanced studies, promotes and supports discovery research, and fosters innovation by encouraging Canadian companies to participate and invest in postsecondary research projects. Program to support interdisciplinary collaborative research with a strong focus on knowledge translation (KT) which demonstrate health and economic benefits to Canadians in order to develop more effective health services, products and/or a strengthened health care system. 3 Slide courtesy of Krissy Davidge, CIHR

4 Funding Cycle Schedule Letter of Intent due: May 15, 2013 Peer review of LOI: June/July 2013 Invitations for full application sent in July 150 invited Full applications due: October 1, 2013 Peer Review in January 2014 Funding Start Date April 1, % success rate Review of your LOI (SPARC or FoM GD team) Bakery method (first come first served) 4

5 Available Funds Overall Funding Profile $21 million available in general pool Funding partners: Institute of Aging, Institute of Cancer Research and Institute of Musculoskeletal Health and Arthritis Individual Projects 175 K/ avg. year for 2 3 years no maximum value funded/year non-renewable 5

6 Priority Areas for Funding Partners Institute of Aging Mobility and functional autonomy Maintaining cognitive ability Using IT for enhanced independence Age adapted work environments Institute of Cancer Research Development of novel tools for diagnostics, point of care, personal screening, improving current outcomes New tools and techniques for research Institute of Musculoskeletal Health and Arthritis Tissue injury, repair and replacement Pain, disability and chronic disease Physical activity, mobility and health 6

7 CHRP Overview Knowledge User / Translation requires KT plan requires active participation and support (can be in-kind) must be able to use results outside research setting Canadian based organization representative should have a non-academic role Natural Science/Engineering Research Nominated principal applicant Must be NSERC eligible Goals 1) To fund collaborative research which produces results that are likely to be relevant to Canadians either from a health or economic standpoint. Minimum of 3 groups 2) Training of HQP in successful for interdisciplinary eligibility environments Health Researchers other principal applicant must be CIHR eligible can not be the knowledge user 7

Knowledge Translation Definition: a dynamic and iterative process that includes synthesis, dissemination, exchange and ethically-sound application of knowledge to improve health of Canadians,

8 Knowledge Translation Definition: a dynamic and iterative process that includes synthesis, dissemination, exchange and ethically-sound application of knowledge to improve health of Canadians, provide more effective health services and products, and strengthens the health care system. Graham, I.D., et al. J. Contin Educ Health Prof. 2006; 26(1):

9 Knowledge Translation Component can be a private, public or a volunteer organization support offered can be in-kind must demonstrate that the partnership will produce research which will benefit Canadians either economically or in terms of health care (in support letter) The role of the knowledge translation/user partner: demonstrate interest in the project (letters of support, in-kind contributions) participate in all stages of the research (help to develop the proposal, interact with researchers and students, provide input to the project) contribute to evaluation of research outcome (validation) provide guidance and assistance with translation or dissemination of results 9

10 Limitations on Selection of KT Partners Partners in the private sector must demonstrate how results will translate to economic impact must have Canadian R&D or manufacturing operations in the area of the application to be considered eligible Non-Canadian Organizations if no suitable KU/KT organization available, or willing to participate an outside organization can be engaged at both LOI and full application stage must provide justification for choice of KU/KT partner ie. provide s from companies turning down your requests for partnerhship must still prove anticipated health and economic benefits to Canadians Federally Funded Organizations Groups receiving federal funding (ie. NCE) can not act as KU/KT partner 10

Microneedle-Based Painless Drug Monitoring System in

work Transplant patients need antirejection drugs for life

simplify things In addition, we don t like blood draws

11 Microneedle-Based Painless Drug Monitoring System in Interstitial Fluid Therapeutic drug monitoring is too much work Transplant patients need antirejection drugs for life Need to check concentration weekly Nanotechnology could simplify things In addition, we don t like blood draws Slide provided courtesy of Dr. Urs Hafeli, Faculty of Pharmaceutical Sciences

12 Components of this example NSERC Developing and optimizing technology User friendly systems Hardware/software CIHR Examining new treatment method Clearly identified patient group working to test in hospitals Knowledge Translation Commercialization strategy 12

13 Rapid in vitro Screening of Nanomaterial Distribution and Toxicity Objective: Development of novels screening tools for the rapid biodistribution and toxicity assessment of nanomaterials NSERC Evaluate NP aggregation and association kinetics with serum proteins Evaluate NP partitioning into model cell membranes Using blood vessel mimetic flow chambers CIHR Evaluate NP accumulation in chicken embryos and zebrafish biodistribution and toxicity studies Knowledge Translation Cytodiagnostics (in-kind support) Health Canada, Healthy Environments and Consumer Safety (health policy outcome) Provided courtesy of Dr. David Cramb, Department of Chemistry, University of Calgary 13

14 Building a CHRP Team NSERC Partner Development of new technology Can include prototype development Can lead to patent development Development of new biological agent/protein or therapy CIHR Partner Investigation of new disease Investigation of new treatment Large scale application of smaller study Apply the technology from NSERC group to test group cells, animals, people Knowledge Translation / Knowledge User Can commercialize the research outcomes Can use research outcomes to improve healthcare or health system in a measureable way Hospitals, divisions, research teams can by KT/KU * CHRP does not fund randomized control trials or clinical trials 14

15 Letter of Intent May 15 Successful LOIs Ensure you meet criteria for evaluation interdisciplinary/ collaborative, KT plan, KU involvement Use headings! Scientific Merit Quality of Research Project Appropriateness of Team Potential Impact Knowledge Translation Training of HQP Summary Review Criteria 2 reviewers Assess how well project aligns with program objectives rating provided Based on title choose title carefully Note: At the LOI stage partnership details and letters are not required for KU/KT. **Special instructions on webpage** 15

16 Full Applications Review & Evaluation Reviewed by 3 reviewers Merit Review (50% scientific / 50% Impact) Scientific merit Quality of project Choice of team members Potential impact Is the project novel? Have the researchers clearly defined the scope and expected outcomes of the project? Is the proposed methodology feasible? Have they clearly demonstrated the engagement of the KU/KT partner? Does this involve training of HQP? Projects 3.5 or higher for both science & impact considered for funding 16

17 Tips for Successful Proposals Choose your teams carefully. Have well defined objectives, scope, deliverables, decision points and measureable outcomes. Have a well defined knowledge translation plan with appropriate KT/KU partner. * Partner should benefit from being involved. Use the program criteria as headings. Take care to adequately address budget justification, in-kind contributions etc. 17

18 Special Instructions for LOI Submission All participants (with exception of collaborators) must register with CIHR for a PIN NPA and other principal applicant must submit CCV at LOI stage Upload a blank budget page on ResearchNet One KT/KU must be identified, you may enter $1 in contribution budget area Upload blank partner details and partner letters in order to submit application 18

19 Help & Resources Department of Medicine (Research Coordinator) Coordinate reviews FoM & SPARC Check eligibility Answer questions Sample CHRP grant Facilitate signatures Ethics approval SPARC Support Programs to Advance Research Capacity Can view successful LOIs which have been funded Facilitate finding partners CHRP Program Contact: 19

Shaping the future of health research funding: Trends, issues, opportunities

Shaping the future of health research funding: Trends, issues, opportunities Ryerson University June, 2012 Dr. Joy Johnson Scientific Director CIHR Institute of Gender and Health What is CIHR? One of three